dapt thermo fisher scientific Search Results


dapt thermo fisher scientific  (Thermo Fisher)
95
Thermo Fisher dapt thermo fisher scientific
Dapt Thermo Fisher Scientific, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dapt thermo fisher scientific/product/Thermo Fisher
Average 95 stars, based on 1 article reviews
dapt thermo fisher scientific - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
dapt 10 um  (Fisher Scientific)
90
Fisher Scientific dapt 10 um
a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5 -EGFP + crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification of crypt domains per organoid with and without UK-5099 ( n = 6 experimental replicates). c, Quantification of organoid formation from crypts from proximal small intestine with and without UK-5099 ( n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow cytometry for cells in (c) showing percent GFP positive ( n = 3 replicates per condition). e, Human ascending colon crypts treated with wENR basal media (set to 1) or media containing UK-5099 or CHIR+VAL ( n = 5 patients with 6–8 individual cultures per patient sample). f, Representative images and quantification of crypt domains in organoids maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids treated <t>with</t> <t>IWP-2</t> and <t>DAPT</t> to promote differentiation with and without UK-5099. Blue arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, Organoid formation from crypts treated with the indicated single, double, and triple drug combinations (CHIR = CHIR99021 and VAL = valproic acid) ( n = 10 experimental replicates, p values are for each treatment compared to wENR). i, Transcript abundance in organoids showing the ratio of UK5099 treated to control ( n = 3 experimental replicates, p values calculated for each transcript compared to wENR). j, Heat map for additional transcripts from (i) . k, Probability of cells infected with virus containing empty vector or both MPC1-iRFP and MPC2-mCherry also being GFP positive ( n = 4 independent organoids with at least 15 infected cells counted). Data are mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars, 50 μm ( a ,) and 100 μm ( f, g ). P values for 6h were calculated by One-way ANOVA with correction for multiple comparisons. All other p values were calculated using Student’s t -test.
Dapt 10 Um, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dapt 10 um/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
dapt 10 um - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
γ-secretase inhibitor dapt n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine t-butyl ester  (Fisher Scientific)
90
Fisher Scientific γ-secretase inhibitor dapt n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine t-butyl ester
a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5 -EGFP + crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification of crypt domains per organoid with and without UK-5099 ( n = 6 experimental replicates). c, Quantification of organoid formation from crypts from proximal small intestine with and without UK-5099 ( n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow cytometry for cells in (c) showing percent GFP positive ( n = 3 replicates per condition). e, Human ascending colon crypts treated with wENR basal media (set to 1) or media containing UK-5099 or CHIR+VAL ( n = 5 patients with 6–8 individual cultures per patient sample). f, Representative images and quantification of crypt domains in organoids maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids treated <t>with</t> <t>IWP-2</t> and <t>DAPT</t> to promote differentiation with and without UK-5099. Blue arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, Organoid formation from crypts treated with the indicated single, double, and triple drug combinations (CHIR = CHIR99021 and VAL = valproic acid) ( n = 10 experimental replicates, p values are for each treatment compared to wENR). i, Transcript abundance in organoids showing the ratio of UK5099 treated to control ( n = 3 experimental replicates, p values calculated for each transcript compared to wENR). j, Heat map for additional transcripts from (i) . k, Probability of cells infected with virus containing empty vector or both MPC1-iRFP and MPC2-mCherry also being GFP positive ( n = 4 independent organoids with at least 15 infected cells counted). Data are mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars, 50 μm ( a ,) and 100 μm ( f, g ). P values for 6h were calculated by One-way ANOVA with correction for multiple comparisons. All other p values were calculated using Student’s t -test.
γ Secretase Inhibitor Dapt N [N (3,5 Difluorophenacetyl) L Alanyl] S Phenylglycine T Butyl Ester, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/γ-secretase inhibitor dapt n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine t-butyl ester/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
γ-secretase inhibitor dapt n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine t-butyl ester - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
dapt  (Fisher Scientific)
90
Fisher Scientific dapt
a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5 -EGFP + crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification of crypt domains per organoid with and without UK-5099 ( n = 6 experimental replicates). c, Quantification of organoid formation from crypts from proximal small intestine with and without UK-5099 ( n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow cytometry for cells in (c) showing percent GFP positive ( n = 3 replicates per condition). e, Human ascending colon crypts treated with wENR basal media (set to 1) or media containing UK-5099 or CHIR+VAL ( n = 5 patients with 6–8 individual cultures per patient sample). f, Representative images and quantification of crypt domains in organoids maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids treated <t>with</t> <t>IWP-2</t> and <t>DAPT</t> to promote differentiation with and without UK-5099. Blue arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, Organoid formation from crypts treated with the indicated single, double, and triple drug combinations (CHIR = CHIR99021 and VAL = valproic acid) ( n = 10 experimental replicates, p values are for each treatment compared to wENR). i, Transcript abundance in organoids showing the ratio of UK5099 treated to control ( n = 3 experimental replicates, p values calculated for each transcript compared to wENR). j, Heat map for additional transcripts from (i) . k, Probability of cells infected with virus containing empty vector or both MPC1-iRFP and MPC2-mCherry also being GFP positive ( n = 4 independent organoids with at least 15 infected cells counted). Data are mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars, 50 μm ( a ,) and 100 μm ( f, g ). P values for 6h were calculated by One-way ANOVA with correction for multiple comparisons. All other p values were calculated using Student’s t -test.
Dapt, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dapt/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
dapt - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine tbutyl ester (dapt)  (Fisher Scientific)
90
Fisher Scientific n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine tbutyl ester (dapt)
a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5 -EGFP + crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification of crypt domains per organoid with and without UK-5099 ( n = 6 experimental replicates). c, Quantification of organoid formation from crypts from proximal small intestine with and without UK-5099 ( n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow cytometry for cells in (c) showing percent GFP positive ( n = 3 replicates per condition). e, Human ascending colon crypts treated with wENR basal media (set to 1) or media containing UK-5099 or CHIR+VAL ( n = 5 patients with 6–8 individual cultures per patient sample). f, Representative images and quantification of crypt domains in organoids maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids treated <t>with</t> <t>IWP-2</t> and <t>DAPT</t> to promote differentiation with and without UK-5099. Blue arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, Organoid formation from crypts treated with the indicated single, double, and triple drug combinations (CHIR = CHIR99021 and VAL = valproic acid) ( n = 10 experimental replicates, p values are for each treatment compared to wENR). i, Transcript abundance in organoids showing the ratio of UK5099 treated to control ( n = 3 experimental replicates, p values calculated for each transcript compared to wENR). j, Heat map for additional transcripts from (i) . k, Probability of cells infected with virus containing empty vector or both MPC1-iRFP and MPC2-mCherry also being GFP positive ( n = 4 independent organoids with at least 15 infected cells counted). Data are mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars, 50 μm ( a ,) and 100 μm ( f, g ). P values for 6h were calculated by One-way ANOVA with correction for multiple comparisons. All other p values were calculated using Student’s t -test.
N [N (3,5 Difluorophenacetyl) L Alanyl] S Phenylglycine Tbutyl Ester (Dapt), supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine tbutyl ester (dapt)/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine tbutyl ester (dapt) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
dapt solution  (Fisher Scientific)
90
Fisher Scientific dapt solution
a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5 -EGFP + crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification of crypt domains per organoid with and without UK-5099 ( n = 6 experimental replicates). c, Quantification of organoid formation from crypts from proximal small intestine with and without UK-5099 ( n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow cytometry for cells in (c) showing percent GFP positive ( n = 3 replicates per condition). e, Human ascending colon crypts treated with wENR basal media (set to 1) or media containing UK-5099 or CHIR+VAL ( n = 5 patients with 6–8 individual cultures per patient sample). f, Representative images and quantification of crypt domains in organoids maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids treated <t>with</t> <t>IWP-2</t> and <t>DAPT</t> to promote differentiation with and without UK-5099. Blue arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, Organoid formation from crypts treated with the indicated single, double, and triple drug combinations (CHIR = CHIR99021 and VAL = valproic acid) ( n = 10 experimental replicates, p values are for each treatment compared to wENR). i, Transcript abundance in organoids showing the ratio of UK5099 treated to control ( n = 3 experimental replicates, p values calculated for each transcript compared to wENR). j, Heat map for additional transcripts from (i) . k, Probability of cells infected with virus containing empty vector or both MPC1-iRFP and MPC2-mCherry also being GFP positive ( n = 4 independent organoids with at least 15 infected cells counted). Data are mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars, 50 μm ( a ,) and 100 μm ( f, g ). P values for 6h were calculated by One-way ANOVA with correction for multiple comparisons. All other p values were calculated using Student’s t -test.
Dapt Solution, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dapt solution/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
dapt solution - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5 -EGFP + crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification of crypt domains per organoid with and without UK-5099 ( n = 6 experimental replicates). c, Quantification of organoid formation from crypts from proximal small intestine with and without UK-5099 ( n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow cytometry for cells in (c) showing percent GFP positive ( n = 3 replicates per condition). e, Human ascending colon crypts treated with wENR basal media (set to 1) or media containing UK-5099 or CHIR+VAL ( n = 5 patients with 6–8 individual cultures per patient sample). f, Representative images and quantification of crypt domains in organoids maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids treated with IWP-2 and DAPT to promote differentiation with and without UK-5099. Blue arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, Organoid formation from crypts treated with the indicated single, double, and triple drug combinations (CHIR = CHIR99021 and VAL = valproic acid) ( n = 10 experimental replicates, p values are for each treatment compared to wENR). i, Transcript abundance in organoids showing the ratio of UK5099 treated to control ( n = 3 experimental replicates, p values calculated for each transcript compared to wENR). j, Heat map for additional transcripts from (i) . k, Probability of cells infected with virus containing empty vector or both MPC1-iRFP and MPC2-mCherry also being GFP positive ( n = 4 independent organoids with at least 15 infected cells counted). Data are mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars, 50 μm ( a ,) and 100 μm ( f, g ). P values for 6h were calculated by One-way ANOVA with correction for multiple comparisons. All other p values were calculated using Student’s t -test.

Journal: Nature cell biology

Article Title: Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism

doi: 10.1038/ncb3593

Figure Lengend Snippet: a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5 -EGFP + crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification of crypt domains per organoid with and without UK-5099 ( n = 6 experimental replicates). c, Quantification of organoid formation from crypts from proximal small intestine with and without UK-5099 ( n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow cytometry for cells in (c) showing percent GFP positive ( n = 3 replicates per condition). e, Human ascending colon crypts treated with wENR basal media (set to 1) or media containing UK-5099 or CHIR+VAL ( n = 5 patients with 6–8 individual cultures per patient sample). f, Representative images and quantification of crypt domains in organoids maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids treated with IWP-2 and DAPT to promote differentiation with and without UK-5099. Blue arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, Organoid formation from crypts treated with the indicated single, double, and triple drug combinations (CHIR = CHIR99021 and VAL = valproic acid) ( n = 10 experimental replicates, p values are for each treatment compared to wENR). i, Transcript abundance in organoids showing the ratio of UK5099 treated to control ( n = 3 experimental replicates, p values calculated for each transcript compared to wENR). j, Heat map for additional transcripts from (i) . k, Probability of cells infected with virus containing empty vector or both MPC1-iRFP and MPC2-mCherry also being GFP positive ( n = 4 independent organoids with at least 15 infected cells counted). Data are mean ± s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars, 50 μm ( a ,) and 100 μm ( f, g ). P values for 6h were calculated by One-way ANOVA with correction for multiple comparisons. All other p values were calculated using Student’s t -test.

Article Snippet: To promote robust differentiation IWP-2 (2 uM Fisher Scientific #35–331-0) and DAPT (10 uM Fisher Scientific #26–341-0) were added to organoid media along with vehicle (DMSO) or UK-5099 (20 uM).

Techniques: Flow Cytometry, Control, Infection, Virus, Plasmid Preparation